STOCK TITAN

Robert W. Duggan receives new PLSE stock option grants (NASDAQ: PLSE)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. director and 10% owner Robert W. Duggan received two stock option grants as equity compensation. He was awarded options for 12,495 shares and 30,000 shares of common stock at an exercise price of $26.89 per share, expiring on June 11, 2036. The options vest over one year, with one grant vesting in equal monthly installments starting on July 11, 2026 and the other vesting in equal quarterly installments starting on September 5, 2026, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider DUGGAN ROBERT W
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 30,000 $0.00 --
Grant/Award Stock Option (right to buy) 12,495 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
  1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Option grant 1 size 12,495 options Stock Option (right to buy) underlying common stock
Option grant 2 size 30,000 options Stock Option (right to buy) underlying common stock
Exercise price $26.89 per share Conversion or exercise price for both option grants
Total underlying shares 42,495 shares Sum of underlying common stock for both grants
Expiration date June 11, 2036 Expiration for both stock option grants
Monthly vesting start July 11, 2026 First installment for one option grant
Quarterly vesting start September 5, 2026 First installment for the other option grant
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 26.8900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option will vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DUGGAN ROBERT W

(Last)(First)(Middle)
C/O PULSE BIOSCIENCES, INC.
3957 POINT EDEN WAY

(Street)
HAYWARD CALIFORNIA 94545

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$26.8906/11/2026A30,000 (1)06/11/2036Common Stock30,000$030,000D
Stock Option (right to buy)$26.8906/11/2026A12,495 (2)06/11/2036Common Stock12,495$012,495D
Explanation of Responses:
1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
/s/ Kenneth B. Stratton06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PLSE reporting person Robert W. Duggan report?

Robert W. Duggan reported receiving two stock option grants in Pulse Biosciences. The awards cover 12,495 and 30,000 underlying common shares and were granted at an exercise price of $26.89 per share as part of his equity compensation.

Are Robert W. Duggan’s PLSE transactions open-market buys or option grants?

The transactions are option grants, not open-market share purchases. Both are coded as grant or award acquisitions, giving rights to buy 12,495 and 30,000 PLSE shares at a fixed exercise price of $26.89 per share.

How do the new Pulse Biosciences options granted to Robert W. Duggan vest?

The options vest over one year, subject to continued service. One grant vests in equal monthly installments starting July 11, 2026, while the other vests in equal quarterly installments starting September 5, 2026, increasing his exercisable position over time.

What is the expiration date of Robert W. Duggan’s new PLSE stock options?

Both stock option grants expire on June 11, 2036. After that date, any unexercised options become worthless, so the effective life of these compensation awards is about 10 years from the grant date.

How many Pulse Biosciences shares can Robert W. Duggan acquire from these option grants?

The two grants together cover 42,495 underlying common shares of Pulse Biosciences. One option award relates to 12,495 shares, and the other to 30,000 shares, all exercisable at an exercise price of $26.89 per share once vested.